Streetbeat News

Earnings

HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) reported better-than-expected Q4 earnings, beating analyst estimates with earnings of 1 cent per share and quarterly sales of $246.62 million. The company also issued strong guidance for Q1 2024 and FY 2024, expecting to surpass $1 billion in revenue. Following the report, HIMS shares surged 31.9% to $13.52. Analysts from Truist Securities, Piper Sandler, Citigroup, and Guggenheim have subsequently raised their price targets on HIMS.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 6:10 pm

BSY

Bentley Systems' shares dropped following the announcement of Q4 revenue results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 6:08 pm

RCM

Coliseum Capital Management, a major shareholder of R1 RCM Inc (NASDAQ:RCM), believes New Mountain Capital's $13.75/share acquisition offer undervalues R1 RCM. Despite missing Q4 revenue expectations, R1 RCM reported a significant year-over-year revenue increase and a positive GAAP net income, contrasting with the previous year's loss. The company's CEO highlighted achievements and future growth plans, including revenue and EBITDA projections for 2024. RCM shares rose 4% to $14.45.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 6:06 pm

KRYS

Krystal Biotech, Inc. (NASDAQ:KRYS) exceeded Q4 expectations with earnings of 30 cents per share against an expected loss of 39 cents, and sales of $42.14 million over the $28.61 million forecast. The success follows the FDA approval and launch of VYJUVEK for dystrophic epidermolysis bullosa. The company anticipates FY24 R&D and SG&A expenses between $150 million to $175 million. Following the report, KRYS shares rose by 5.3% to $165.35. Guggenheim and Citigroup raised their price targets for KRYS to $175 and $195, respectively.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 6:03 pm

CDNA

CareDx (NASDAQ:CDNA) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $-0.27. Historical data shows that CareDx has previously beaten EPS estimates, leading to significant share price movements. The company's stock has declined 41.31% over the last 52 weeks, trading at $8.92 as of February 26. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:02 pm

CPRX

Catalyst Pharmaceuticals (NASDAQ:CPRX) is scheduled to release its quarterly earnings report on 2024-02-28, with analysts expecting an EPS of $0.26. The company's past earnings performance shows a mix of beats and misses, with the share price reacting variably. Shares were trading at $14.18 as of February 26, marking a 7.47% decline over the last 52 weeks. Investors will be keenly watching for not just the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:02 pm

JBI

Janus Intl Gr (NYSE:JBI) is scheduled to release its quarterly earnings report on February 28, 2024, with an expected EPS of $0.26. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, JBI has shown a mixed reaction to earnings reports, with share price movements varying post-announcement. The stock has seen a 44.83% increase over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $0.01. Historical data shows the company has previously beaten EPS estimates, leading to positive stock price movements. Shares are currently trading at $137.65, down 3.01% over the last year. Investors are looking for a beat on the EPS estimate and positive future guidance.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

EDIT

Editas Medicine (NASDAQ:EDIT) is scheduled to release its quarterly earnings report on February 28, 2024, with an expected EPS of $-0.54. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Editas Medicine has had mixed results in beating EPS estimates, with share price reactions varying. The stock was trading at $8.06 as of February 26, showing a slight increase of 0.68% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

SRI

Stoneridge (NYSE:SRI) is anticipated to report a Q4 earnings per share (EPS) of $0.10 on February 28, 2024. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Stoneridge has had a mixed performance in beating EPS estimates, with a notable 2.6% share price increase following last quarter's earnings beat. However, the stock has seen a 21.87% decline over the past 52 weeks, indicating potential concerns among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm